| Revenue Growth | North America up 12%; EMEA up 5%; IFC revenue $5.6M vs $3.9M. |
|---|---|
| Mgmt Confidence | High confidence in long-term mission despite transient geopolitical and FX headwinds. |
| Demand Visibility | Strong momentum in BCA member centers; international illuminator placements exceeding expectations. |
| Margin Trends | Gross margin 52.4% vs 53.4% YoY; improved sequentially from 51.4% in Q2. |
| Op. Leverage | Operating expenses grew 5% vs 10% revenue growth, showing positive leverage. |
| Pricing Power | Transitioning IFC to kit model offers more attractive gross margins despite lower price. |
| Vol vs Price | Volume-led; North American platelet kits and doses increased 5% year-over-year. |
| Segment Growth | IFC sales volume increased 7% sequentially; 90% of IFC now kit-based. |
| New Clients | Deepened Blood Centers of America (BCA) relationship; Grady Memorial Hospital adoption. |
| Capex & Debt | Generated $3M cash flow; $57.1M cash balance; refreshed shelf registration statement. |
| Regulatory | CE Mark delayed to late 2027; FDA requested incremental data for INT200. |
| Commentary | Focusing on establishing Intercept as global standard of care via clinical evidence. |
| New Launches | Phase III Redis top-line results; INT200 illuminator international rollout continuing. |
Growth
Product revenue rose 10% to $57.7M; North America up 12%, EMEA up 5%.
Outlook
Reaffirmed 2026 revenue guidance of $229M-$231M; CE Mark clearance now expected late 2027.
Risks
Management used vague language regarding specific FDA data requirements for INT200, delaying approval visibility.
The company's earnings call, NASDAQ: CERS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Cerus Corp: key numbers
- Share price
- $1.86Close, Nov 16
- Market cap
- $376M
- Shares outstanding
- 201.95MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cerus Corp
All →Cerus Q3 2026 Results: Net Loss of $550K, Loss Widens
For the quarter ended September 30, 2026, Cerus Corporation reported product revenue of $57.7 million, a 9.5% increase over the prior year, and achieved a narrow net loss of $0.6 million. The company significantly reduced its nine-month net loss from $13.5 million in 2025 to $5.2 million in 2026, driven by higher gross profits and lower research and development expenses.
- Key figure
- Net loss $550K
Cerus Financial Results
Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.
- Term
- Q3 2026
“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”
Vivek Jayaraman, Cerus’s president and chief executive officer